Skip to main content

Advertisement

Figure 2 | Experimental & Translational Stroke Medicine

Figure 2

From: Docosahexaenoic acid complexed to human albumin in experimental stroke: neuroprotective efficacy with a wide therapeutic window

Figure 2

Histopathology: (A) Computer-generated MosaiX processed images (Zeiss Axio Imager.M1; AxioVision Release 4.6.3) of Nissl stained paraffin-embedded brain sections from rats treated with saline, DHA (5 mg/kg), Albumin (0.63 g/kg) or DHA-Albumin (5 mg/kg + 0.32, 0.63 or 1.25 g/kg). Saline and Alb-treated rats show large cortical and subcortical infarction. Rats treated with DHA shows less extensive damage. In contrast, DHA-Albumin treated rats show very small infarction, mostly in the subcortical area. (B) Coronal brain diagram showing locations of regions for cell counts in cortex (A, B and C) and subcortex (S). Number of GFAP positive astrocytes, ED-1 positive microglia cells, NeuN positive neurons and SMI-71 positive vessels were counted on day 7 after 2 h of MCAo. DHA-Alb treatment decreased ED-1, increased NeuN, GFAP positive cell counts and SMI-71 positive vessels. Data are mean ±SEM; n=5-7 per group. *P <0.05 versus saline group; # P <0.05 versus Alb group (repeated-measures ANOVA followed by Bonferroni tests).

Back to article page